Novasep and Nilsan Nishotech to Install Continuous Chromatography System at Laurus Labs
Novasep, a supplier of life-sciences manufacturing solutions, and its partner Nilsan Nishotech Systems, a process engineering specialist in India, announced the commissioning of a continuous chromatography Varicol system at Laurus Labs, an API manufacturer based in India.
Novasep, a supplier of life-sciences manufacturing solutions, and its partner Nilsan Nishotech Systems, a process engineering specialist in India, announced the commissioning of a continuous chromatography Varicol system at Laurus Labs, an API manufacturer based in India.
This is the first time Laurus Labs will use a continuous chromatography system at multi-ton scale to obtain high productivity and cost-efficient chiral molecule separation.
Varicol continuous chromatography is used to separate enantiomers from racemic mixtures. A key feature is the solvent recycling unit associated with the chromatography system enabling the process to exhibit low solvent consumption (more than 99.9% solvent recovery).
According to the press release, Novasep’s Varicol is capable of achieving separation of 500 kg per day in Laurus Labs’ production of API. Prior to the installation, Novasep conducted a feasibility study at its R&D laboratory in Pompey, France, to evaluate the continuous process on a small-scale.
Source: Novasep
Drug Solutions Podcast: Novel Drug Delivery Approaches: Refining AAV Vector Deliveries
May 30th 2025In this podcast episode, we discuss novel approaches to drug delivery, specifically regarding adeno-associated virus (AAV) vectors, as viewed by two industry experts who recently exhibited at the annual ASGCT meeting.
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Prokaryotics Licenses Gram-Negative Antibiotic Potentiator from Northern Antibiotics
June 26th 2025Prokaryotics will gain worldwide rights to develop, manufacture, and commercialize NAB741, a non-bioactive polymyxin designed to increase permeability of the outer membrane of Gram-negative bacteria.
